Dr. De Haes has also held senior positions in the pharmaceutical industry with Sandoz Pharma (now part of Novartis), where he led the development and commercialisation of the company's first biotech product. Dr. De Haes is a Medical Doctor, University of Leuven, Belgium, and holds a corporate MBA, University of St Thomas, Minneapolis, USA.
Professor Collen founded ThromboGenics as a spin-out of the University of Leuven and has led the Company since its inception. He has been pivotal in the Company's success, which was originally financed from the royalties of tPA, a product for the treatment of heart attacks, which was commercialised by the leading US biotech company Genentech. In the last several years, he has made a major contribution to the building of ThromboGenics' exciting development pipeline, as well as leading the Company through its successful IPO on Euronext Brussels in June 2006.
Dr. Patrik De Haes, commenting on his appointment said, "I am very pleased to have been appointed as the CEO of ThromboGenics at a very exciting time for the Company. Our recent licensing deal with Roche for TB-403, has allowed us to focus and invest in the clinical development of microplasmin, a product which we believe could be a major advance in the treatment of a number of important eye diseases. I look forward to continue working with Desire and the rest of the senior management team, to ensure we deliver significant shareholder value from our most attractive pipeline."
Professor Desire Collen, ThromboGenics' Chairman said, "I am glad that
Patrik has agreed to become ThromboGenics' new
|SOURCE ThromboGenics NV|
Copyright©2008 PR Newswire.
All rights reserved